Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

FDA May Approve New Opioid That’s 5- to 10-Times Stronger Than Fentanyl [Fortune]

AcelRx Pharmaceuticals, Inc. (ACRX) 
Last acelrx pharmaceuticals, inc. earnings: 3/16 07:35 am Check Earnings Report
US:NASDAQ Investor Relations: ir.acelrx.com/investor-relations
Company Research Source: Fortune
Almost half of all overdose deaths in the United States is caused by Fentanyl , according to research released earlier this summer. So it may seem surprising that the U.S. Food and Drug Administration (FDA) is considering giving approval to AcelRx Pharmaceuticals for Dsuvia, its single-dose 30 microgram tablet of synthetic opioid sufentanil. Sufentanil is five to 10 times stronger than fentanyl and 500 times stronger than morphine, according to Marketwatch . The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee recently voted 10-3 in favor of U.S. approval of Dsuvia. The FDA is not required to but often follows the committee’s recommendations. But even among committee members, there is disagreement about the necessity of releasing another potent opioid to the public. Dr. Raeford Brown, the chair of the committee and a professor of anesthesiology and pediatrics at the University of Kentucky, expressed concern about Dsuvia, which he noted comes in a form Show less Read more
Impact Snapshot
Event Time:
ACRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ACRX alerts
Opt-in for
ACRX alerts

from News Quantified
Opt-in for
ACRX alerts

from News Quantified